Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA: Generics Rule 'Complicated,' But Not About Litigation

This article was originally published in Scrip

Executive Summary

The FDA's reasons for proposing a rule that would permit generic drug makers to independently revise their product labeling to add new safety updates before regulators review or approve such changes – just like brand-name manufacturers already do – are "complicated," declared Stephen Ostroff, who up until last week had been serving as the agency's acting commissioner for much of the past year.

Advertisement
Advertisement
UsernamePublicRestriction

Register